A redesigned Pfizer vaccine is expected to arrive this coming March as stated by the company's CEO, Albert Bourla. He said that the new vaccine is specifically developed against the new Omicron variant.
This illustration picture taken on November 23, 2020 shows a bottle reading "Vaccine Covid-19" and a syringe next to the Pfizer and Biontech logo. - The European Commission has signed five contracts to pre-order vaccines, among which with the U.S.-German company Pfizer-BioNTech (up to 300 million doses). (Photo by JOEL SAGET / AFP)
Right now, the global pandemic is worsening as more infectious strains are being discovered by medical experts and scientists across the globe.
Because of this, some schools in the United States are now deciding to cancel the classes to prevent further infections. Omicron is not the only variant that worries people.
Recently, TechTimes reported that the new COVID-19 variant Deltacron was identified in Cyprus. On the other hand, the World Health Organization also confirmed another strain called IHU.
Redesigned Pfizer Vaccine to Arrive
According to Reuters' latest report, Pfizer is now working with BioNTech SE to create the new vaccine. This new vaccine is expected to contain the previous version of the vaccine and the new one.
A nurse shows a container of Pfizer-BioNTech COVID-19 vaccine after it was used to vaccinate the first five staff members at Roseland Community Hospital on December 17, 2020 in Chicago, Illinois. Roseland Community Hospital is situated in the Roseland neighborhood on the city's far south side. The neighborhood's population is 95 percent black. The COVID-19 death rate among black residents in Chicago is nearly double that of the city’s white residents.
Also Read: Omicron Variant To Be Tackled By New Air Decontamination Device From Canadian Company Ti-DOX
"This vaccine will be ready in March. We [are] already starting manufacturing some of these quantities at risk," said Bourla via CNBC.
He added that the new Pfizer vaccine is expected to provide better protection against Omicron infections. As of the moment, the efficiency of the new medicine against Omicron is still unknown.
But, you can expect more information from Pfizer as days go by. Meanwhile, the CEO said that they are preparing to file for a U.S. regulatory approval for the new vaccine.
He added that switching to the new vaccine's development will not be an issue since Pfizer has already built a better manufacturing capacity.
Why the Redesigned Vaccine is Important
Albert released a new statement saying that two regular vaccine doses are not enough to prevent Omicron infections. He added that they don't offer strong protection against the new variant.
Pfizer's CEO also explained that the new COVID-19 strain is harder to target. If this is true, then the upcoming redesigned vaccine will be quite essential.
However, this will still depend on the results of the vaccine's upcoming tests.
For more news updates about Pfizer's new vaccine and other COVID-19 topics, always keep your tabs open here at TechTimes.
Related Article: 'Flurona': Is It a COVID-19 Mutation? Cases Found in LA, Other US States
This article is owned by TechTimes
Written by: Griffin Davis
Related Article
New COVID-19 Deltacron Combines Omicron, Delta Strains! Variant Mostly Detected in Hospitalized Patients
WHO Discovers New COVID-19 Variant! Is the IHU Something to Worry About?
Omicron Variant Battle: Canadian Company's New Air Decontamination Device Aims To Help Control Spread
